公开(公告)号：US20110318337A1

公开(公告)日：2011-12-29

申请号：US13115810

申请日：2011-05-25

申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

IPC分类号： A61K39/395 ,  A61P11/00 ,  A61P29/00

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

公开(公告)号：US20090324585A1

公开(公告)日：2009-12-31

申请号：US12482703

申请日：2009-06-11

申请人： William H. Robinson ,  V. Michael Holers ,  Andrew L. Rozelle

发明人： William H. Robinson ,  V. Michael Holers ,  Andrew L. Rozelle

IPC分类号： A61K39/395 ,  A61K38/00

CPC分类号： A61K38/17 ,  A01K67/0278 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0368 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18

摘要： The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of, or treat osteoarthritis. In other embodiments, compounds with specific inhibition of a component in a particular pathway in the complement system, such as the alternative, mannose binding lectin, and/or classical pathway, are administered to a subject having osteoarthritis or at risk of developing osteoarthritis.

摘要翻译： 本公开涉及通过施用调节补体系统中的一种或多种组分的化合物来治疗骨关节炎和预防骨关节炎的方法和组合物。 在一个实施方案中，施用抑制补体系统中的成分的化合物以预防，延缓进展或治疗骨关节炎。 在其它实施方案中，对具有骨关节炎或有发展为骨关节炎风险的受试者施用对补体系统中特定途径中的组分具有特异性抑制的化合物，例如替代性甘露糖结合凝集素和/或经典途径。

公开(公告)号：US10239937B2

公开(公告)日：2019-03-26

申请号：US13505150

申请日：2010-11-05

申请人： V. Michael Holers ,  Antonio M. Risitano

发明人： V. Michael Holers ,  Antonio M. Risitano

IPC分类号： C07K16/18 ,  C07K14/47 ,  C07K14/705 ,  A61K38/17

摘要： Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.

公开(公告)号：US20130190477A1

公开(公告)日：2013-07-25

申请号：US13697693

申请日：2011-05-13

申请人： James M. Kovacs ,  Jonathan P. Hannan ,  V. Michael Holers

发明人： James M. Kovacs ,  Jonathan P. Hannan ,  V. Michael Holers

IPC分类号： C07K19/00

CPC分类号： C07K19/00 ,  C07K14/472

摘要： Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.

摘要翻译： 本文提供了针对可选择性递送补体活性调节剂的可溶性蛋白质的组合物和方法。 这些调节剂的靶向递送通过选择性地突变组合物的靶蛋白部分中对应于CR2的至少前两个N末端SCR结构域的特定氨基酸而实现。 取决于引入靶向部分的突变体的特定组合，补体活性调节剂可以选择性递送到需要补体系统激活或抑制的位点处的CR2的特定配体。